X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com/news-release/2024/04/24/2868978/18362/en/Amarin-Applauds-HealthyWomen-s-Citizen-s-Petition-Urging-FDA-To-Take-Further-Action-On-Fenofibrate-Prescribing-in-Patients-at-Risk-of-Cardiovascular-Event.html
https://www.globenewswire.com/news-release/2024/04/22/2866832/18362/en/Amarin-Announces-Results-of-Annual-General-Meeting-of-Shareholders.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-17-2024-82633.pdf
https://www.globenewswire.com/news-release/2024/04/15/2862719/18362/en/Amarin-to-Report-First-Quarter-2024-Financial-Results-and-Host-Conference-Call-on-May-1-2024.html
https://www.globenewswire.com/news-release/2024/04/08/2859112/18362/en/Amarin-Highlights-Key-Data-Providing-Mechanistic-Insights-into-Eicosapentaenoic-Acid-EPA-at-ACC-24.html
https://www.globenewswire.com/news-release/2024/04/06/2858811/18362/en/New-REDUCE-IT-Analyses-Show-VASCEPA-VAZKEPA-Icosapent-Ethyl-Benefit-in-High-Risk-Cardiovascular-Disease-Patient-Subgroups.html
https://www.globenewswire.com/news-release/2024/04/03/2856860/18362/en/Amarin-Provides-Update-on-VAZKEPA-Icosapent-Ethyl-Intellectual-Property-Portfolio-in-Europe.html
https://www.fiercepharma.com/pharma/teva-follows-suit-after-hikmas-2023-complaint-arguing-amarin-locked-drug-ingredient-supply
https://www.globenewswire.com//news-release/2024/02/15/2829894/18362/en/Amarin-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-Conference-on-February-29-2024.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-14-2024-75684.pdf
https://www.globenewswire.com//news-release/2024/01/22/2812941/18362/en/Amarin-Chairman-CEO-Issue-Letter-to-Shareholders.html
https://www.globenewswire.com//news-release/2024/01/10/2806970/18362/en/Amarin-Provides-Preliminary-Fourth-Quarter-2023-Selected-Financials-and-Outlines-Key-Priorities-For-2024.html
https://www.globenewswire.com//news-release/2023/12/11/2793825/18362/en/Amarin-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/11/12/2778635/18362/en/New-REDUCE-IT-Analyses-Show-VASCEPA-icosapent-ethyl-Associated-with-29-Percent-Relative-Risk-Reduction-Compared-with-Placebo-in-Prespecified-Subgroup-of-Patients-with-Metabolic-Syn.html
https://www.globenewswire.com//news-release/2023/11/01/2770981/18362/en/Amarin-Reports-Third-Quarter-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2023/10/31/2770478/18362/en/Amarin-Appoints-Jonathan-Provoost-Executive-Vice-President-Chief-Legal-Compliance-Officer.html
https://www.globenewswire.com//news-release/2023/10/26/2767462/18362/en/Latest-Research-Evaluating-VASCEPA-VAZKEPA-icosapent-ethyl-and-Subgroups-from-the-REDUCE-IT-Landmark-Outcomes-Trial-to-be-Presented-at-the-American-Heart-Association-AHA-Scientific.html
https://www.globenewswire.com//news-release/2023/10/19/2763140/18362/en/Amarin-to-Report-Third-Quarter-2023-Financial-Results-and-Host-Conference-Call-on-November-1-2023.html
https://www.globenewswire.com//news-release/2023/09/12/2741592/18362/en/Amarin-to-Present-at-the-2023-Cantor-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2023/08/09/2722118/18362/en/Amarin-Provides-Pricing-Reimbursement-Updates-for-VAZKEPA-icosapent-ethyl-in-The-Netherlands-and-Italy.html
https://www.globenewswire.com/news-release/2023/08/08/2720436/18362/en/Amarin-And-Neopharm-Announce-Exclusive-Commercialization-Agreement-for-VAZKEPA-Icosapent-Ethyl-in-Israel.html
https://www.globenewswire.com/news-release/2023/08/07/2719579/18362/en/Scottish-Medicines-Consortium-Accepts-VAZKEPA-icosapent-ethyl-to-Help-Reduce-Cardiovascular-Risk-for-Patients-in-Scotland-1.html
https://www.globenewswire.com/news-release/2023/08/02/2716719/18362/en/Amarin-Reports-Second-Quarter-2023-Financial-Results.html
https://www.globenewswire.com/news-release/2023/07/31/2714836/18362/en/Amarin-and-Lotus-Pharmaceuticals-Announce-Exclusive-Partnership-Agreement-to-Commercialize-Vazkepa-Icosapent-Ethyl-in-Southeast-Asia-and-South-Korea.html
https://www.globenewswire.com/news-release/2023/07/26/2711275/18362/en/Latest-Research-Evaluating-Clinical-Benefits-of-VASCEPA-VAZKEPA-icosapent-ethyl-to-be-Presented-at-the-European-Society-of-Cardiology-ESC-Congress.html
https://www.globenewswire.com/news-release/2023/07/25/2710859/18362/en/Amarin-Receives-Positive-Recommendation-from-Spanish-Drug-Pricing-Committee-for-National-Reimbursement-of-VAZKEPA-icosapent-ethyl-in-Spain.html
https://www.fiercepharma.com/pharma/amarin-axes-120-its-385-employees-hires-new-ceo-holt
https://www.globenewswire.com/news-release/2023/07/20/2708141/18362/en/Amarin-Board-of-Directors-Announces-Executive-Compensation-Program-for-New-President-and-CEO-Patrick-Holt.html
https://www.fiercepharma.com/pharma/amarin-axes-120-its-385-employees-hires-new-ceo-holt
https://www.globenewswire.com/news-release/2023/07/18/2706866/18362/en/Amarin-Appoints-Patrick-Holt-as-President-and-Chief-Executive-Officer.html
https://www.globenewswire.com/news-release/2023/07/18/2706852/18362/en/Amarin-Implements-Organizational-Restructuring-to-Strengthen-the-Company-While-Driving-Patient-Access-to-VASCEPA-VAZKEPA-Globally.html
https://www.pharmaceutical-technology.com/news/sfda-amarin-vascepa-cardiovascular/
https://www.globenewswire.com/news-release/2023/06/01/2680863/18362/en/Amarin-to-Present-at-Two-Upcoming-Investor-Conferences.html
https://www.globenewswire.com/news-release/2023/06/01/2680082/18362/en/Amarin-Partner-EddingPharm-Receives-Regulatory-Approval-for-Vascepa-Icosapent-Ethyl-in-Mainland-China.html
https://www.globenewswire.com/news-release/2023/05/12/2667968/18362/en/Amarin-Highlights-New-Data-Providing-Potential-Mechanistic-Insight-into-Vascepa-Vazkepa-Icosapent-Ethyl-Reduction-of-Cardiovascular-Events.html
https://endpts.com/amylyx-welcomes-former-alnylam-exec-to-help-expand-relyvrio-amarin-plugs-in-an-interim-chief/
https://www.globenewswire.com/news-release/2023/04/19/2649963/18362/en/Amarin-to-Report-First-Quarter-2023-Financial-Results-and-Host-Conference-Call-on-May-3-2023.html
https://www.fiercepharma.com/pharma/after-former-ceo-split-amarin-declares-new-interim-ceo-us-business-president-aaaron-berg
https://www.globenewswire.com/news-release/2023/04/17/2647757/18362/en/Amarin-Names-Aaron-Berg-Interim-President-Chief-Executive-Officer-and-Adds-Oliver-O-Connor-to-Company-s-Board-of-Directors.html
https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-vazkepar-icosapent-ethyl-approved-israels
https://www.globenewswire.com/news-release/2023/04/04/2640591/18362/en/Amarin-Announces-VAZKEPA-Icosapent-Ethyl-Approved-by-Israel-s-Ministry-of-Health.html
https://www.fiercepharma.com/pharma/after-amarins-clash-sarissa-ceo-mikhail-hits-exit#:~:text=In%20the%20wake%20of%20a,His%20departure%20is%20effective%20immediately
https://www.globenewswire.com/news-release/2023/03/16/2628628/18362/en/Reconstituted-Amarin-Board-Ready-for-the-Challenge-of-Unlocking-True-Potential-of-VASCEPA-VAZKEPA-Icosapent-Ethyl.html
https://www.fiercepharma.com/pharma/sarissas-overhaul-amarins-board-complete-resignation-7-holdover-members
https://www.globenewswire.com/news-release/2023/03/06/2621550/18362/en/Amarin-Announces-Board-Departures.html
https://www.globenewswire.com/news-release/2023/03/06/2621064/18362/en/Amarin-Highlights-New-Evidence-of-Therapeutic-Value-of-EPA-in-Reducing-Cardiovascular-Events-in-At-Risk-Patients-Presented-at-ACC-23-WCC.html
https://www.globenewswire.com/news-release/2023/03/05/2620629/18362/en/Amarin-Announces-New-REDUCE-IT-Data-at-ACC-23-WCC-Showing-Benefit-of-VASCEPA-VAZKEPA-Icosapent-Ethyl-in-High-Risk-Patients-with-a-Recent-Acute-Coronary-Syndrome-Event.html
https://endpts.com/alex-denner-secures-victory-in-amarin-vote-ousting-chair-and-adding-supporters-to-board/
https://www.globenewswire.com/news-release/2023/02/28/2617338/18362/en/Amarin-Announces-Preliminary-Voting-Results-Following-2023-General-Meeting-of-Shareholders.html
https://www.globenewswire.com/news-release/2023/02/28/2617048/18362/en/Amarin-and-CSL-Seqirus-Announce-Exclusive-License-and-Distribution-Agreement-to-Commercialize-VAZKEPA-Icosapent-Ethyl-in-Australia-and-New-Zealand.html
Market Place
Share 
